AC Immune S.A.
ACIU · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $939 | $1,306 | $990 | $1,137 |
| % Growth | -28.1% | 31.9% | -12.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $939 | $1,306 | $990 | $1,137 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $13,071 | $16,826 | $15,916 | $15,785 |
| G&A Expenses | $3,567 | $3,896 | $4,443 | -$1,841 |
| SG&A Expenses | $3,567 | $3,896 | $4,443 | -$1,841 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $467 | -$28 | $1 | $5,811 |
| Operating Expenses | $17,105 | $20,694 | $20,360 | $19,755 |
| Operating Income | -$16,166 | -$19,388 | -$19,370 | -$18,618 |
| % Margin | -1,721.6% | -1,484.5% | -1,956.6% | -1,637.5% |
| Other Income/Exp. Net | $308 | -$1,801 | $341 | $2,824 |
| Pre-Tax Income | -$15,858 | -$21,189 | -$19,029 | -$15,794 |
| Tax Expense | $0 | $0 | $0 | $3 |
| Net Income | -$15,858 | -$21,189 | -$19,029 | -$15,797 |
| % Margin | -1,688.8% | -1,622.4% | -1,922.1% | -1,389.4% |
| EPS | -0.16 | -0.21 | -0.19 | -0.14 |
| % Growth | 23.8% | -10.5% | -35.7% | – |
| EPS Diluted | -0.16 | -0.21 | -0.19 | -0.15 |
| Weighted Avg Shares Out | 99,113 | 100,631 | 100,409 | 110,062 |
| Weighted Avg Shares Out Dil | 99,113 | 100,631 | 100,409 | 100,859 |
| Supplemental Information | – | – | – | – |
| Interest Income | $320 | $458 | $687 | $889 |
| Interest Expense | $0 | $50 | $54 | $30 |
| Depreciation & Amortization | $340 | $623 | $612 | $529 |
| EBITDA | -$15,518 | -$20,516 | -$18,363 | -$15,235 |
| % Margin | -1,652.6% | -1,570.9% | -1,854.8% | -1,339.9% |